UPDATE: Stifel Nicolaus Initiates Buy, $15 PT on Supernus Pharmaceuticals; Emerging CNS Pipeline

Stifel Nicolaus initiates its coverage on Supernus Pharmaceuticals

with a Buy rating and a price target of $15 per share. Stifel Nicolaus comments, "With extensive experience in product development, first as a subsidiary of Shire and then independently, the company is developing a broad central nervous system (CNS) portfolio with proprietary extended-release technologies that have been validated through numerous marketed drugs. Supernus has two near-term opportunities in epilepsy, SPN-538 and SPN-804, approaching FDA decision in the coming months, as well as a balanced pipeline of other CNS drugs for attention deficit hyperactivity disorder (ADHD) and depression, with a view to providing enhanced therapeutic benefits for specific unmet needs in each indication." SUPN closed at $5.94 on Friday.